严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株KP.3.1.1和XEC通过N端结构域突变增强免疫逃逸 - Suppr

Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.

作者信息

Liu Jingyi, Yu Yuanling, Jian Fanchong, Yang Sijie, Song Weiliang, Wang Peng, Yu Lingling, Shao Fei, Cao Yunlong

机构信息

Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; College of Future Technology, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.

Changping Laboratory, Beijing, China.

出版信息

Lancet Infect Dis. 2025 Jan;25(1):e6-e7. doi: 10.1016/S1473-3099(24)00738-2. Epub 2024 Nov 22.

DOI:10.1016/S1473-3099(24)00738-2

PMID:39586310

Abstract

摘要

相似文献

Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.

Lancet Infect Dis. 2025 Jan;25(1):e6-e7. doi: 10.1016/S1473-3099(24)00738-2. Epub 2024 Nov 22.

Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.

J Virol. 2025 Apr 15;99(4):e0024225. doi: 10.1128/jvi.00242-25. Epub 2025 Mar 26.

Immune Evasion, Cell-Cell Fusion, and Spike Stability of the SARS-CoV-2 XEC Variant: Role of Glycosylation Mutations at the N-terminal Domain.

bioRxiv. 2024 Nov 13:2024.11.12.623078. doi: 10.1101/2024.11.12.623078.

Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC.

Cell Rep. 2025 Apr 22;44(4):115543. doi: 10.1016/j.celrep.2025.115543. Epub 2025 Apr 8.

Comparative analysis of replication and immune evasion among SARS-CoV-2 subvariants BA.2.86, JN.1, KP.2, and KP.3.

mBio. 2025 Apr 29:e0350324. doi: 10.1128/mbio.03503-24.

SARS-CoV-2 XEC: A Genome-Based Survey.

Microorganisms. 2025 Jan 24;13(2):253. doi: 10.3390/microorganisms13020253.

Entry Efficiency, Protease Dependence, and Antibody-Mediated Neutralization of SARS-CoV-2 Sublineages KP.3.1.1 and XEC.

Vaccines (Basel). 2025 Apr 3;13(4):385. doi: 10.3390/vaccines13040385.

Recent SARS-CoV-2 evolution trajectories indicate the emergence of Omicron's several subvariants and the current rise of KP.3.1.1 and XEC.

Virology. 2025 Jun;607:110508. doi: 10.1016/j.virol.2025.110508. Epub 2025 Mar 20.

AlphaFold2 Modeling and Molecular Dynamics Simulations of the Conformational Ensembles for the SARS-CoV-2 Spike Omicron JN.1, KP.2 and KP.3 Variants: Mutational Profiling of Binding Energetics Reveals Epistatic Drivers of the ACE2 Affinity and Escape Hotspots of Antibody Resistance.

Viruses. 2024 Sep 13;16(9):1458. doi: 10.3390/v16091458.

Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants.

mBio. 2025 May 14;16(5):e0046425. doi: 10.1128/mbio.00464-25. Epub 2025 Mar 26.

引用本文的文献

Emerging SARS-CoV-2 variants: genomic shifts, immune evasion, and therapeutic perspectives.

Mol Biol Rep. 2025 Sep 10;52(1):886. doi: 10.1007/s11033-025-11009-w.

From immune evasion to broad binding: computational optimization of SARS-CoV-2 RBD-targeting nanobody.

Front Immunol. 2025 Aug 14;16:1637955. doi: 10.3389/fimmu.2025.1637955. eCollection 2025.

Multiscale Modeling and Dynamic Mutational Profiling of Binding Energetics and Immune Escape for Class I Antibodies with SARS-CoV-2 Spike Protein: Dissecting Mechanisms of High Resistance to Viral Escape Against Emerging Variants.

Viruses. 2025 Jul 23;17(8):1029. doi: 10.3390/v17081029.

Adjuvant combination and antigen multimerization shape neutralizing antibody and T cell responses to a SARS-CoV-2 RBD subunit vaccine.

Front Immunol. 2025 Jul 17;16:1610422. doi: 10.3389/fimmu.2025.1610422. eCollection 2025.

Adaptation of the Vaccine Prophylaxis Strategy to Variants of the SARS-CoV-2 Virus.

Vaccines (Basel). 2025 Jul 17;13(7):761. doi: 10.3390/vaccines13070761.

The XEC Variant: Genomic Evolution, Immune Evasion, and Public Health Implications.

Viruses. 2025 Jul 15;17(7):985. doi: 10.3390/v17070985.

Structural and functional insights into the evolution of SARS-CoV-2 KP.3.1.1 spike protein.

Cell Rep. 2025 Jul 4;44(7):115941. doi: 10.1016/j.celrep.2025.115941.

Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection.

Vaccines (Basel). 2025 Jun 12;13(6):635. doi: 10.3390/vaccines13060635.

Discovery of Synergistic Broadly Neutralizing Antibodies Targeting Non-Dominant Epitopes on SARS-CoV-2 RBD and NTD.

Vaccines (Basel). 2025 May 30;13(6):592. doi: 10.3390/vaccines13060592.

A non-spike nucleocapsid R204P mutation in SARS-CoV-2 Omicron XEC enhances inflammation and pathogenicity.

bioRxiv. 2025 May 30:2025.05.28.656516. doi: 10.1101/2025.05.28.656516.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献